HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Dipyridamole (Persantine)

Subscribe to New Research on Dipyridamole

A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)

Also Known As:

Persantine; Miosen; Antistenocardin; Apo-Dipyridamole; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cerebrovase; Cléridium; Curantil; Curantyl; Dipyramidole; IPRAD Brand of Dipyridamole; Kurantil; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Persantin; Berlin Chemie Brand of Dipyridamole; Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-

Networked: 2873 relevant articles (200 outcomes, 546 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 319
    - Dipyridamole: 2873

Experts

1.	Picano, Eugenio: 34 articles (06/2015 - 04/2002)
2.	Cortigiani, Lauro: 20 articles (06/2015 - 07/2002)
3.	Sicari, Rosa: 18 articles (06/2015 - 02/2003)
4.	Rigo, Fausto: 15 articles (06/2015 - 11/2003)
5.	Gherardi, Sonia: 14 articles (06/2015 - 08/2005)
6.	Bigi, Riccardo: 13 articles (05/2012 - 07/2002)
7.	Diener, Hans-Christoph: 13 articles (01/2012 - 01/2005)
8.	Picano, E: 12 articles (12/2003 - 01/2000)
9.	Bovenzi, Francesco: 11 articles (06/2015 - 02/2006)
10.	Galderisi, Maurizio: 9 articles (07/2014 - 07/2002)

Related Diseases

1.	Stroke (Strokes) 09/15/1998 - "The sustained release dipyridamole produced a significant risk reduction of 16% for stroke, 15% for stroke and/or death but no significant reduction of mortality. " 07/01/2008 - "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition. " 11/01/2013 - "A recent review discussed results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extended release dipyridamole in secondary stroke prevention. " 07/01/2008 - "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention. " 07/01/2008 - "Based on the results from these 2 large, randomized trials, ASA + dipyridamole was more effective than ASA monotherapy as first-line therapy for secondary stroke prevention in these patients with a history of minor stroke or TIA of noncardioembolic etiology."
2.	Coronary Artery Disease (Coronary Atherosclerosis) 10/01/1995 - "In patients with chronic coronary artery disease and a low incidence of cardiac events, dipyridamole echocardiography was effective in prognostic stratification, and positive low work load exercise ECG results were a reliable predictor of subsequent events. " 07/15/1992 - "Intravenous dipyridamole planar thallium-201 imaging is a safe and effective test for detection and prognosis of coronary artery disease (CAD) in the general population. " 03/01/1997 - "Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease." 02/01/1992 - "To evaluate the efficacy of stress technetium-99m MMI (N-2-methoxy-2-methyl propyl isonitrile) myocardial perfusion scintigraphy (Tc-99m MMI) using intravenous dipyridamole for detection of coronary artery disease (CAD), we collected 66 cases (53 men, 13 women, aged 40-79 years old) between Sept. " 02/01/1988 - "Thus, dipyridamole cardiac imaging is helpful in the diagnosis of coronary artery disease and in risk stratification."
3.	Myocardial Infarction 12/01/1993 - "Dipyridamole echocardiography was well tolerated by elderly patients and proved to be very effective in prognostic stratification early after uncomplicated acute myocardial infarction, even when only survival was considered." 09/01/1997 - "Echocardiographic imaging during dipyridamole infusion is superior to sestamibi scintigraphy for predicting events after uncomplicated myocardial infarction." 03/01/1990 - "We have not found dipyridamole to be effective in the dog with coronary artery constriction and find no substantial evidence that it is effective in preventing myocardial infarction in man. " 11/15/2010 - "No previous study has assessed the possible role of dipyridamole for treatment of no-reflow during acute myocardial infarction (AMI). " 05/01/2010 - "Three trials included the endpoint of myocardial infarction in patients receiving ER dipyridamole. "
4.	Myocardial Ischemia (Ischemic Heart Diseases) 03/01/1991 - "Thus, evaluation of early washout ratios (WR-25) after dipyridamole injection is a valuable method to increase sensitivity in assessing regional myocardial perfusion abnormality and is helpful in detection of ischemic heart disease, even with multivessel disease." 08/01/2001 - "Dipyridamole nuclear myocardial perfusion test is a safe and effective alternative to exercise nuclear perfusion testing for detecting myocardial ischemia. " 05/01/2010 - "One randomized controlled trial evaluated the efficacy of ER dipyridamole in patients with preexisting ischemic heart disease and found no evidence of increased risk of cardiac events in this population. " 01/01/1996 - "In response to dipyridamole introduction improved myocardial perfusion was registered in 4 out of 6 patients, 1 patient showed signs of transient myocardial ischemia, 1 patient had stable defects of myocardial blood supply. " 07/01/2002 - "Study aim was the prospective assessment of the impact of dipyridamole-induced myocardial ischemia on the signal-averaged ECG. "
5.	Ischemia 03/01/1997 - "Results for sensitivity (89%) and negative predictive value (83%) in group 3 were significantly better than those in group 2 (71% [p = 0.03] and 56% [p = 0.002], respectively) and not significantly different from those in group 1. The polar maps of 20 patients studied with an without dipyridamole at the same exercise level revealed a significantly greater extent of ischemia in each territory and in a global assessment (19 + 20% vs. 8 + 11%, p < 0.0001) when dipyridamole was administered during physical exercise. " 08/01/1989 - "The increase in rate-pressure product (RPP = mm Hg x beats/min x 100) measured during the exercise stress test in the patients in group I was significantly greater than that determined during dipyridamole-induced ischemia (204 +/- 41 versus 145 +/- 33, p less than 0.01). " 06/01/1983 - "Rapid atrial pacing performed before and at 60, 90, and 120 minutes after dipyridamole failed to demonstrate any significant reduction in pacing threshold or evidence of increased ischemia after dipyridamole. " 06/01/2010 - "The aim of this study was to compare the feasibility and diagnostic accuracy of high-volume rate 3DE with state-of-the-art two-dimensional echocardiography (2DE) in detecting ischemia during dipyridamole-induced stress (DipSE). " 06/01/2010 - "This study tries to evaluate the prevalence and significance of ECG changes after dipyridamole infusion and their relation to ischemia in myocardial perfusion single-photon emission computed tomography (SPECT). "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	clopidogrel (Plavix)
3.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
4.	Thallium
5.	Adenosine
6.	Ticlopidine (Ticlid)
7.	Prednisolone (Predate)
8.	Dobutamine
9.	Warfarin (Coumadin)
10.	Dipyridamole (Persantine)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Renal Dialysis (Hemodialysis)
4.	Prostheses and Implants (Prosthesis)
5.	Angioplasty (Angioplasty, Transluminal)